Literature DB >> 21163305

Specificity and sensitivity of the Abeta oligomer ELISA.

Andrea C Klaver1, Lynnae M Patrias, John M Finke, David A Loeffler.   

Abstract

Abeta soluble oligomers are believed to play a key role in the development of Alzheimer's disease (AD). An enzyme-linked immunosorbent assay (ELISA) commonly used to measure these proteins uses the same monoclonal antibody as both capture and reporter antibody. The objective of this study was to examine the specificity and sensitivity of this procedure, using monoclonal anti-Abeta antibody 6E10 as capture antibody and biotinylated 6E10 as reporter antibody. At comparable concentrations of Abeta soluble oligomers and low molecular weight (LMW) Abeta peptides, optical density (OD) values were four- to five-fold higher for the oligomer preparation than for the LMW Abeta. The LMW Abeta preparation, when evaluated by western blots of gels run under native conditions, showed only one band even after storage at 4 °C for more than two months, suggesting that the ELISA was detecting Abeta monomer as well as Abeta oligomers. Possible explanations for these results are that (1) the LMW Abeta preparation may contain Abeta oligomer species below the limit of detection of western blot, but still detectable by ELISA, or (2) some nonspecific binding of the LMW Abeta to the ELISA plate may have occurred, allowing its relevant epitope to remain available for binding by the reporter antibody. Because of the possibility that this ELISA may not be oligomer-specific, it seems prudent to suggest that it should be used in combination with other methods, rather than as the sole technique, for measuring Abeta oligomers in biological specimens.
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163305     DOI: 10.1016/j.jneumeth.2010.12.001

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  11 in total

1.  SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease.

Authors:  Kazuma Murakami; Nakaba Murata; Yoshihiro Noda; Shoichi Tahara; Takao Kaneko; Noriaki Kinoshita; Hiroyuki Hatsuta; Shigeo Murayama; Kevin J Barnham; Kazuhiro Irie; Takuji Shirasawa; Takahiko Shimizu
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models.

Authors:  Mikhail A Kostylev; Adam C Kaufman; Haakon B Nygaard; Pujan Patel; Laura T Haas; Erik C Gunther; Alexander Vortmeyer; Stephen M Strittmatter
Journal:  J Biol Chem       Date:  2015-05-27       Impact factor: 5.157

3.  Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls.

Authors:  Thomas J Esparza; Hanzhi Zhao; John R Cirrito; Nigel J Cairns; Randall J Bateman; David M Holtzman; David L Brody
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

4.  Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Authors:  Stephanie M Williams; Philip Schulz; Michael R Sierks
Journal:  Eur J Neurosci       Date:  2015-10-15       Impact factor: 3.386

5.  Cu and Zn coordination to amyloid peptides: From fascinating chemistry to debated pathological relevance.

Authors:  Elena Atrián-Blasco; Paulina Gonzalez; Alice Santoro; Bruno Alies; Peter Faller; Christelle Hureau
Journal:  Coord Chem Rev       Date:  2018-09-15       Impact factor: 22.315

6.  ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Authors:  Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler
Journal:  J Neuroinflammation       Date:  2011-08-09       Impact factor: 8.322

7.  Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease.

Authors:  Susanne Aileen Funke
Journal:  Int J Alzheimers Dis       Date:  2011-11-02

8.  Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody.

Authors:  Katherine L Youmans; Leon M Tai; Takahisa Kanekiyo; W Blaine Stine; Sara-Claude Michon; Evelyn Nwabuisi-Heath; Arlene M Manelli; Yifan Fu; Sean Riordan; William A Eimer; Lester Binder; Guojun Bu; Chunjiang Yu; Dean M Hartley; Mary Jo LaDu
Journal:  Mol Neurodegener       Date:  2012-03-16       Impact factor: 14.195

9.  Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis.

Authors:  Ann Tiiman; Vesna Jelić; Jüri Jarvet; Petter Järemo; Nenad Bogdanović; Rudolf Rigler; Lars Terenius; Astrid Gräslund; Vladana Vukojević
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

10.  Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer's disease diagnosis.

Authors:  Kazuma Murakami; Maki Tokuda; Takashi Suzuki; Yumi Irie; Mizuho Hanaki; Naotaka Izuo; Yoko Monobe; Ken-Ichi Akagi; Ryotaro Ishii; Harutsugu Tatebe; Takahiko Tokuda; Masahiro Maeda; Toshiaki Kume; Takahiko Shimizu; Kazuhiro Irie
Journal:  Sci Rep       Date:  2016-07-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.